Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ClearPoint Neuro, Inc. is a medical technology company operating in the neurosurgery and neuromodulation industries, with a focus on providing precision navigation and delivery solutions for minimally invasive brain procedures. The company develops and commercializes integrated platforms that enable neurosurgeons and interventional neurologists to accurately target and access structures within the brain under real-time imaging guidance.
The company’s primary revenue drivers are capital equipment sales, disposable surgical components, and service and licensing revenue associated with its navigation and delivery platforms. ClearPoint Neuro primarily serves hospitals, academic medical centers, and research institutions involved in functional neurosurgery, neuro-oncology, gene therapy, and drug delivery to the brain. Its strategic advantage lies in MRI-guided accuracy and compatibility with multiple therapeutic modalities. ClearPoint Neuro was founded in 1998 and has evolved from an early-stage navigation technology developer into a platform provider supporting both clinical care and investigational therapies.
Business Operations
ClearPoint Neuro generates revenue through the sale and support of its ClearPoint System, which includes navigation software, hardware components, and single-use surgical disposables. The company also derives revenue from development services and licensing arrangements with biopharmaceutical partners using its technology for clinical trials involving gene therapy, cell therapy, and targeted drug delivery. Operations are structured around providing both clinical workflow solutions and research-enabling infrastructure.
The company operates in both domestic and international markets, with U.S. hospitals representing its core customer base. ClearPoint Neuro controls proprietary MRI-guided navigation software, stereotactic hardware, and delivery cannulas used in neurosurgical procedures. It maintains collaborations with medical device manufacturers and biopharmaceutical companies, and operates through wholly owned subsidiaries, including ClearPoint Neuro, Inc. and ClearPoint Neuro, Ltd., which support U.S. and international activities respectively.
Strategic Position & Investments
ClearPoint Neuro’s strategic direction centers on expanding adoption of its platform in functional neurosurgery while deepening its role as an enabling technology for investigational therapies targeting the brain. Growth initiatives include increasing utilization of disposable products, expanding service and development revenue from life sciences partners, and broadening clinical indications supported by its navigation system.
The company has made targeted investments in product development and regulatory expansion rather than large-scale acquisitions. It has focused on supporting clinical trials for emerging therapies such as gene therapy and cell-based treatments, positioning its platform as a critical infrastructure component for precise intracranial delivery. Notable subsidiaries include ClearPoint Neuro, Ltd., which facilitates international commercialization and regulatory activities.
Geographic Footprint
ClearPoint Neuro is headquartered in the United States, with its principal executive offices located in California. The company’s primary commercial presence is in North America, where it has established relationships with major academic medical centers and hospital systems.
Internationally, ClearPoint Neuro has an expanding footprint across Europe and parts of Asia-Pacific, supported by direct operations and distributor relationships. Through its international subsidiary and partners, the company participates in global clinical research programs and supports multinational clinical trials, extending its operational influence beyond its core U.S. market.
Leadership & Governance
ClearPoint Neuro is led by an executive team with experience in medical devices, neurosurgery-focused technologies, and life sciences partnerships. The leadership emphasizes precision medicine, disciplined capital allocation, and collaboration with clinical and research stakeholders to drive long-term platform adoption.
Key executives include:
- Joe Burnett – President and Chief Executive Officer
- Chris Roberts – Chief Financial Officer
- Robert Newcomb – Chief Technology Officer
- Alison Brown – Chief Operating Officer
The company is governed by a board of directors that includes executives and independent directors with backgrounds in healthcare, finance, and medical technology, supporting oversight, regulatory compliance, and strategic execution.